Sinovac Biotech (SVA) to Supply 900,000 Doses of Its Inactivated

Message Board

| Next

Post# of 7

Posted On: 11/07/2013 9:01:28 AM

Posted By: riddock57

Sinovac Biotech Ltd. (NASDAQ:SVA)

Hepatitis A is a contagious liver disease that results from infection with the Hepatitis A virus. It can range in severity from a mild illness lasting a few weeks to a severe illness lasting several months. Hepatitis A is usually spread when a person ingests fecal matter — even in microscopic amounts — from contact with objects, food, or drinks contaminated by the feces, or stool, of an infected person.

SVA reported that it has been selected by the Jiangsu Centers for Disease Control and Prevention to supply SVA 's inactivated hepatitis A vaccine, Healive, under the Expanded Program of Immunization (EPI) in 2014 to the pediatric population in China's Jiangsu Province.

The total volume of the tender is up to 1.8 million doses. According to the company and as one of the two selected suppliers, SVA will supply 900,000 doses of Healive to Jiangsu province.

Healive is the first inactivated hepatitis A vaccine developed, produced and marketed by a China-based manufacturer. Healive was launched by SVA in 2002 in China and is currently available in adult and pediatric dosage forms. In February 2008, the Chinese government included hepatitis A vaccine in its national immunization program.

SVA is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps, as well as animal rabies vaccine for canines.

More about Sinovac Biotech Ltd. (NASDAQ:SVA) at www.sinovac.com

Orexigen Therapeutics, Inc. (Nasdaq:OREX)

Being overweight or obese isn't a cosmetic problem. Obesity increases the risk of a number of health conditions including hypertension, adverse lipid concentrations, and type 2 diabetes

OREX reported that it has entered into a commercial supply agreement with Sanofi to act as OREX 's contract manufacturer for Contrave(R) (32 mg naltrexone sustained release (SR) / 360 mg bupropion SR) for territories outside North America. Sanofi will manufacture Contrave tablets at one of several facilities in France.

OREX is evaluating Contrave for the management of obesity, including weight loss and maintenance of weight loss, in conjunction with lifestyle modification, and is currently conducting the Light Study, a cardiovascular outcomes trial. An interim analysis of the Light Study is anticipated by early December, enabling the potential resubmission of the Contrave New Drug-Application to the FDA by year end.

OREX has licensed North American Contrave commercial rights to Takeda Pharmaceuticals. OREX owns Contrave rights in Europe and throughout the rest of the world outside of North America and will seek a partner to commercialize Contrave in those territories.

In October OREX submitted a Marketing Authorization Application (MAA) for Contrave to the European Medicines Agency

According to OREX , this agreement with Sanofi expands and diversifies its existing commercial supply network and will help ensure the company will be ready to supply Contrave globally if approved.